

KERYX BIOPHARMACEUTICALS INC
Form DEF 14A
April 29, 2011

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A INFORMATION

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:

o Preliminary Proxy Statement
 o **Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2))**
 x Definitive Proxy Statement
 o Definitive Additional Materials
 o Soliciting Material Pursuant to §240.14a-12

KERYX BIOPHARMACEUTICALS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.
 o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:

(3)

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form DEF 14A

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

TABLE OF CONTENTS

KERYX BIOPHARMACEUTICALS, INC.
750 Lexington Avenue
New York, New York 10022

Dear Stockholder:

You are cordially invited to our 2011 Annual Meeting of Stockholders, to be held at 10:00 a.m. local time, on Tuesday, June 21, 2011, at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016. At the meeting, the stockholders will be asked to (i) elect six directors for a term of one year, (ii) ratify the appointment of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2011, (iii) consider an advisory vote on compensation of our named executive officers, and (iv) consider an advisory vote on the frequency of the advisory vote on compensation of our named executive officers.

You will also have the opportunity to ask questions and make comments at the meeting.

In accordance with the rules and regulations of the Securities and Exchange Commission, we are furnishing our proxy statement and annual report to stockholders for the year ended December 31, 2010 on the Internet. You may have already received our Important Notice Regarding the Availability of Proxy Materials, which was mailed on or about April 29, 2011. That notice described how you can obtain our proxy statement and annual report. You can also receive paper copies of our proxy statement and annual report upon request.

It is important that your stock be represented at the meeting regardless of the number of shares you hold. You are encouraged to specify your voting preferences by marking our proxy card and returning it as directed. If you do attend the meeting and wish to vote in person, you may revoke your proxy at the meeting.

If you have any questions about the proxy statement or the accompanying 2010 Annual Report, please contact James F. Oliviero, our Chief Financial Officer, Treasurer and Corporate Secretary at (212) 531-5965.

We look forward to seeing you at the 2011 Annual Meeting.

Sincerely,
/s/ Ron Bentsur
Ron Bentsur
Chief Executive Officer

April 29, 2011
New York, New York

TABLE OF CONTENTS

KERYX BIOPHARMACEUTICALS, INC.
750 Lexington Avenue
New York, New York 10022

**NOTICE OF 2011 ANNUAL MEETING OF
STOCKHOLDERS**

The 2011 Annual Meeting of Stockholders of Keryx Biopharmaceuticals, Inc. will be held at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016, on Tuesday, June 21, 2011, at 10:00 a.m., local time. At the meeting, stockholders will consider and act on the following items:

1. The election of six directors to our Board of Directors for a term of one year;
2. The ratification of the appointment of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2011;
3. An advisory vote on compensation of our named executive officers;
4. An advisory vote on the frequency of the advisory vote on compensation of our named executive officers; and
5. The transaction of any other business that may properly come before the 2011 Annual Meeting or any adjournment of the 2011 Annual Meeting.

Only those stockholders of record as of the close of business on April 26, 2011, are entitled to vote at the 2011 Annual Meeting or any postponements or adjournments thereof. A complete list of stockholders entitled to vote at the 2011 Annual Meeting will be available for your inspection beginning June 10, 2011, at our offices located at 750 Lexington Avenue, New York, New York 10022, between the hours of 10:00 a.m. and 5:00 p.m., local time, each business day.

YOUR VOTE IS IMPORTANT!

Instructions on how to vote your shares via the Internet are contained on the Important Notice Regarding the Availability of Proxy Materials, which was mailed on or about April 29, 2011. Instructions on how to obtain a paper copy of our proxy statement and annual report to stockholders for the year ended December 31, 2010 are listed on the Important Notice Regarding the Availability of Proxy Materials. These materials can also be viewed online by following the instructions listed on the Important Notice Regarding the Availability of Proxy Materials.

If you received a paper copy of our proxy statement and annual report, you may vote your shares by completing and returning the enclosed proxy card.

Submitting your proxy does not affect your right to vote in person if you decide to attend the 2011 Annual Meeting. You are urged to submit your proxy as soon as possible, regardless of whether or not you expect to attend the 2011 Annual Meeting. You may revoke your proxy at any time before it is exercised at the 2011 Annual Meeting by (i) delivering written notice to our Corporate Secretary, James Oliviero, at our address above, (ii) submitting a later dated proxy card, (iii) voting again via the Internet as described in the Important Notice Regarding the Availability of Proxy Materials, or (iv) attending the 2011 Annual Meeting and voting in person. No revocation under (i) or (ii) will be effective unless written notice or the proxy card is received by our Corporate Secretary at or before the 2011 Annual Meeting.

TABLE OF CONTENTS

When you submit your proxy, you authorize Ron Bentsur and James F. Oliviero to vote your shares at the 2011 Annual Meeting and on any adjournments of the 2011 Annual Meeting in accordance with your instructions.

By Order of the Board of Directors,

/s/ James F. Oliviero

James F. Oliviero

Corporate Secretary

April 29, 2011

New York, New York

TABLE OF CONTENTS

KERYX BIOPHARMACEUTICALS, INC.

**750 Lexington Avenue
New York, New York 10022**

Phone: (212) 531-5965

Fax: (212) 531-5961

PROXY STATEMENT

This proxy statement and the accompanying proxy card are being made available via Internet access, beginning on or about April 29, 2011, to the owners of shares of common stock of Keryx Biopharmaceuticals, Inc. (the Company, our, we, or Keryx) as of April 26, 2011, in connection with the solicitation of proxies by our Board of Directors for our 2011 Annual Meeting of Stockholders (the Annual Meeting). On or about April 29, 2011, we sent an Important Notice Regarding the Availability of Proxy Materials to our stockholders. If you received this notice by mail, you will not automatically receive by mail our proxy statement and annual report to stockholders for the year ended December 31, 2010. If you would like to receive a printed copy of our proxy statement, annual report and proxy card, please follow the instructions for requesting such materials in the notice. Upon request, we will promptly mail you paper copies of such materials free of charge.

The Annual Meeting will take place at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016 on Tuesday, June 21, 2011, at 10:00 a.m., local time. Our Board of Directors encourages you to read this document thoroughly and take this opportunity to vote, via proxy, on the matters to be decided at the Annual Meeting. As discussed below, you may revoke your proxy at any time before your shares are voted at the Annual Meeting.

TABLE OF CONTENTS

Table of Contents

Proxy Statement	
<u>Questions and Answers</u>	<u>1</u>
<u>Why did I receive an Important Notice Regarding the Availability of Proxy Materials?</u>	<u>1</u>
<u>What is the purpose of the Annual Meeting?</u>	<u>1</u>
<u>Who is entitled to vote at our Annual Meeting?</u>	<u>1</u>
<u>How do I vote?</u>	<u>1</u>
<u>What is a proxy?</u>	<u>1</u>
<u>How will my shares be voted if I vote by proxy?</u>	<u>1</u>
<u>How do I revoke my proxy?</u>	<u>2</u>
<u>Is my vote confidential?</u>	<u>2</u>
<u>How are votes counted?</u>	<u>2</u>
<u>What constitutes a quorum at the Annual Meeting?</u>	<u>2</u>
<u>What vote is required to elect our directors for a one-year term?</u>	<u>2</u>
<u>What vote is required to ratify UHY LLP as our independent registered public accounting firm for the year ending December 31, 2011?</u>	<u>3</u>
<u>How will the outcome of the non-binding advisory vote on the compensation of our named executive officers be determined?</u>	<u>3</u>
<u>How will the outcome of the non-binding advisory vote on the frequency of the advisory vote on compensation of our named executive officers be determined?</u>	<u>3</u>
<u>What percentage of our outstanding common stock do our directors and executive officers own?</u>	<u>3</u>
<u>Who was our independent public accountant for the year ending December 31, 2010? Will they be represented at the Annual Meeting?</u>	<u>3</u>
<u>How can I obtain a copy of our annual report on Form 10-K?</u>	<u>3</u>
<u>Corporate Governance</u>	<u>4</u>
<u>Our Board of Directors</u>	<u>4</u>
<u>Communicating with the Board of Directors</u>	<u>6</u>
<u>Audit Committee</u>	<u>6</u>
<u>Compensation Committee</u>	<u>7</u>
<u>Nominating Process</u>	<u>7</u>
<u>Code of Ethics</u>	<u>8</u>
<u>Independent Registered Public Accounting Firm Fees and Other Matters</u>	<u>9</u>
<u>Audit Fees</u>	<u>9</u>
<u>Audit-Related Fees</u>	<u>9</u>
<u>Tax Fees</u>	<u>9</u>
<u>All Other Fees</u>	<u>9</u>
<u>Pre-Approval of Services</u>	<u>9</u>
<u>Report of the Audit Committee</u>	<u>11</u>
<u>Our Executive Officers</u>	<u>12</u>
<u>Executive Officers</u>	<u>12</u>
<u>Compensation Discussion and Analysis</u>	<u>13</u>

TABLE OF CONTENTS

<u>Report of the Compensation Committee</u>	<u>18</u>
<u>Risk Assessment of Compensation Programs</u>	<u>19</u>
<u>Executive Compensation</u>	<u>20</u>
<u>Summary Compensation Table</u>	<u>20</u>
<u>Grants of Plan-Based Awards For Fiscal Year 2010</u>	<u>20</u>
<u>Employment Agreements</u>	<u>21</u>
<u>Outstanding Equity Awards at 2010 Fiscal Year End</u>	<u>21</u>
<u>Option Exercises and Stock Vested in Fiscal Year 2010</u>	<u>22</u>
<u>Potential Payments upon Termination or Change in Control</u>	<u>22</u>
<u>Director Compensation</u>	<u>26</u>
<u>Director Compensation Program</u>	<u>26</u>
<u>2010 Director Compensation</u>	<u>27</u>
<u>Compensation Committee Interlocks and Insider Participation</u>	<u>29</u>
<u>Section 16(a) Beneficial Ownership Reporting Compliance</u>	<u>30</u>
<u>Related-Person Transactions</u>	<u>31</u>
<u>Stock Ownership of Our Directors, Executive Officers, and 5% Beneficial Owners</u>	<u>32</u>
<u>Proposal One: Election of Directors; Nominees</u>	<u>33</u>
<u>Proposal Two: Ratification of Appointment of UHY LLP as Our Independent Registered Public Accounting Firm</u>	<u>34</u>
<u>Proposal Three: Advisory Vote on Compensation of Our Named Executive Officers</u>	<u>35</u>
<u>Proposal Four: Advisory Vote on the Frequency of the Advisory Vote on Compensation of Our Named Executive Officers</u>	<u>36</u>
<u>Additional Information</u>	<u>37</u>
<u>Householding of Annual Meeting Materials</u>	<u>37</u>
<u>Stockholder Proposals for Our 2012 Annual Meeting</u>	<u>37</u>
<u>Other Matters</u>	<u>37</u>
<u>Solicitation of Proxies</u>	<u>37</u>
<u>Incorporation of Information by Reference</u>	<u>37</u>

TABLE OF CONTENTS

QUESTIONS AND ANSWERS

Q. *Why did I receive an Important Notice Regarding the Availability of Proxy Materials?*

In accordance with Securities and Exchange Commission rules, instead of mailing a printed copy of our proxy materials, we may send an Important Notice Regarding the Availability of Proxy Materials to stockholders. All stockholders will have the ability to access the proxy materials on a website referred to in the notice or to request a printed set of these materials at no charge. You will not receive a printed copy of the proxy materials unless you specifically request one from us. Instead, the notice instructs you as to how you may access and review all of the important information contained in the proxy materials via the Internet and submit your vote via the Internet.

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 21, 2011. The proxy statement is available at www.proxyvote.com.

Q. *What is the purpose of the Annual Meeting?*

At the Annual Meeting, our stockholders will act upon the matters outlined in the Notice of 2011 Annual Meeting of Stockholders accompanying this proxy statement, including (i) the election of six directors to our Board of Directors for a term of one year, (ii) the ratification of the appointment of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2011, (iii) an advisory vote on compensation of our named executive officers, (iv) an advisory vote on the frequency of the advisory vote on compensation of our named executive officers, and (v) the transaction of any other business that may properly come before the 2011 Annual Meeting or any adjournment thereof.

Q. *Who is entitled to vote at our Annual Meeting?*

The record holders of our common stock at the close of business on the record date, April 26, 2011, may vote at the Annual Meeting. Each share of our common stock is entitled to one vote. There were 61,933,210 shares of common stock outstanding on the record date and entitled to vote at the Annual Meeting. A list of stockholders entitled to vote at the Annual Meeting, including the address of and number of shares held by each stockholder of record, will be available for your inspection beginning Friday, June 10, 2011, at our offices located at 750 Lexington Avenue, New York, New York 10022, between the hours of 10:00 a.m. and 5:00 p.m., local time, each business day.

Q. *How do I vote?*

You may vote in person at the Annual Meeting, by use of a proxy card if you receive a printed copy of our proxy materials, via Internet as directed in our Important Notice Regarding the Availability of Proxy Materials, or by telephone as indicated in the proxy card.

Q. *What is a proxy?*

A proxy is a person you appoint to vote your shares of our common stock on your behalf. If you are unable to attend the Annual Meeting, our Board of Directors is seeking your appointment of a proxy so that your shares of our common stock may be voted. If you vote by proxy, you will be designating Ron Bentsur, our Chief Executive Officer, and James F. Oliviero, our Chief Financial Officer, Treasurer and Corporate Secretary, as your proxies. Mr. Bentsur and/or Mr. Oliviero may act on your behalf and have the authority to appoint a substitute to act as your proxy.

Q. *How will my shares be voted if I vote by proxy?*

Your proxy will be voted according to the instructions you provide. **If you complete and submit your proxy but do not otherwise provide instructions on how to vote your shares, your shares will be voted (i) FOR the individuals nominated to serve as members of our Board of Directors, (ii) FOR the ratification of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2011, (iii) FOR the non-binding proposal to approve the compensation of our named executive officers, and (iv) FOR a frequency of every two years for future nonbinding stockholder advisory votes to approve the compensation of our named executive officers.** Presently, our Board of Directors does not know of any other matter that may come before the

TABLE OF CONTENTS

Annual Meeting. However, your proxies are authorized to vote on your behalf, using their discretion, on any other business that properly comes before the Annual Meeting.

Q. ***How do I revoke my proxy?***

A. You may revoke your proxy at any time before your shares are voted at the Annual Meeting by:
delivering written notice to our Corporate Secretary, James F. Oliviero, at our address above;
submitting a later dated proxy card or voting again via the Internet as described in the Important Notice Regarding the Availability of Proxy Materials ; or
attending the 2011 Annual Meeting and voting in person.

Q. ***Is my vote confidential?***

A. Yes. All votes remain confidential, unless you provide otherwise.

Q. ***How are votes counted?***

Before the Annual Meeting, our Board of Directors will appoint one or more inspectors of election for the meeting. A. The inspector(s) will determine the number of shares represented at the meeting, the existence of a quorum and the validity and effect of proxies. The inspector(s) will also receive, count, and tabulate ballots and votes and determine the results of the voting on each matter that comes before the Annual Meeting. Abstentions and votes withheld, and shares represented by proxies reflecting abstentions or votes withheld, will be treated as present for purposes of determining the existence of a quorum at the Annual Meeting. They will not be considered as votes for or against any matter for which the stockholder has indicated their intention to abstain or withhold their vote. Broker or nominee non-votes, which occur when shares held in street name by brokers or nominees who indicate that they do not have discretionary authority to vote on a particular matter, will not be considered as votes for or against that particular matter. Broker and nominee non-votes will be treated as present for purposes of determining the existence of a quorum, and may be entitled to vote on certain matters at the Annual Meeting.

Q. ***What constitutes a quorum at the Annual Meeting?***

In accordance with Delaware law (the law under which we are incorporated) and our amended and restated bylaws, the presence at the Annual Meeting, by proxy or in person, of the holders of a majority of the shares of our common stock outstanding on the record date constitutes a quorum, thereby permitting the stockholders to conduct business A. at the Annual Meeting. Abstentions, votes withheld, and broker or nominee non-votes will be included in the calculation of the number of shares considered present at the Annual Meeting for purposes of determining the existence of a quorum.

If a quorum is not present at the Annual Meeting, a majority of the stockholders present in person and by proxy may adjourn the meeting to another date. If an adjournment is for more than 30 days or a new record date is fixed for the adjourned meeting by our Board of Directors, we will provide notice of the adjourned meeting to each stockholder of record entitled to vote at the adjourned meeting. At any adjourned meeting at which a quorum is present, any business may be transacted that might have been transacted at the originally called meeting.

Q. ***What vote is required to elect our directors for a one-year term?***

The affirmative vote of a plurality of the votes of the shares present, in person or by proxy, at the Annual Meeting is required for the election of each of the nominees for director. Plurality means that the nominees receiving the A. largest number of votes up to the number of directors to be elected at the Annual Meeting will be duly elected as directors. Abstentions, votes withheld, and broker or nominee non-votes will not affect the outcome of director elections.

TABLE OF CONTENTS

Q. *What vote is required to ratify UHY LLP as our independent registered public accounting firm for the year ending December 31, 2011?*

A. The affirmative vote of a majority of the shares present, in person or by proxy, and entitled to vote at the Annual Meeting is required to approve the ratification of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2011. Abstentions and votes withheld will have the same effect as a negative vote. However, broker or nominee non-votes, and shares represented by proxies reflecting broker or nominee non-votes, will not have the effect of a vote against this proposal as they are not considered to be present and entitled to vote on this matter.

Q. *How will the outcome of the non-binding advisory vote on the compensation of our named executive officers be determined?*

A. The affirmative vote of a majority of the shares present, in person or by proxy, and entitled to vote at the Annual Meeting is required to adopt the non-binding advisory vote on the compensation of our executive officers. Abstentions and votes withheld will have the same effect as a negative vote. However, broker or nominee non-votes, and shares represented by proxies reflecting broker or nominee non-votes, will not have the effect of a vote against this proposal as they are not considered to be present and entitled to vote on this matter.

Q. *How will the outcome of the non-binding advisory vote on the frequency of the advisory vote on compensation of our named executive officers be determined?*

A. The frequency of the non-binding advisory vote on compensation of our named executive officers receiving the greatest number of votes every three years, every two years or every year will be the frequency that stockholders approve.

Q. *What percentage of our outstanding common stock do our directors and executive officers own?*

A. As of April 20, 2011, our directors and executive officers owned, or have the right to acquire, approximately 3.3% of our outstanding common stock. See the discussion under the heading "Stock Ownership of Our Directors, Executive Officers, and 5% Beneficial Owners" on page 32 for more details.

Q. *Who was our independent public accountant for the year ending December 31, 2010? Will they be represented at the Annual Meeting?*

A. UHY LLP is the independent registered public accounting firm that audited our financial statements for the year ending December 31, 2010. We expect a representative of UHY LLP to be present at the Annual Meeting. The representative will have an opportunity to make a statement and will be available to answer your questions.

Q. *How can I obtain a copy of our annual report on Form 10-K?*

A. We have filed our annual report on Form 10-K for the year ended December 31, 2010, with the Securities and Exchange Commission, or the SEC. The annual report on Form 10-K is also included in the 2010 Annual Report to Stockholders. You may obtain, free of charge, a copy of our annual report on Form 10-K, including financial statements and exhibits, by writing to our corporate secretary, James F. Oliviero, or by email at info@keryx.com. Upon request, we will also furnish any exhibits to the annual report on Form 10-K as filed with the SEC.

TABLE OF CONTENTS**CORPORATE GOVERNANCE****Our Board of Directors**

Our amended and restated bylaws provide that the Board of Directors shall consist of one or more members, as determined from time to time by resolution of the Board of Directors. Currently, our Board of Directors consists of six members. The following individuals are being nominated to serve on our Board of Directors (See Proposal 1 Election of Directors; Nominees):

Name	Age	Position	Director Since
Michael P. Tarnok	56	Chairman of the Board	2007
Ron Bentsur	45	Director and Chief Executive Officer	2009
Kevin J. Cameron	42	Director	2007
Joseph Feczko, M.D.	62	Director	2010
Wyche Fowler, Jr.	70	Director	2006
Jack Kaye	67	Director	2006

The Board of Directors does not have a formal policy regarding the separation of the roles of Chief Executive Officer and Chairman of the Board of Directors, as the Board of Directors believes that it is in the best interests of the Company to make that determination based on the direction of the Company and the current membership of the Board of Directors. The Board of Directors has determined that having a director who is not an executive officer serve as the Chairman is in the best interest of the Company's stockholders at this time. This structure allows the Chief Executive Officer to focus on the management of the Company's day-to-day operations.

Keryx has a risk management program overseen by Ron Bentsur, our Chief Executive Officer. Mr. Bentsur identifies material risks and prioritizes them for our Board of Directors. Our Board of Directors regularly reviews information regarding our credit, liquidity, and operations, as well as the risks associated with each.

The corporate governance standards adopted by the Nasdaq Stock Market, or Nasdaq, require that a majority of the members of our Board of Directors be independent as Nasdaq defines that term. Additionally, the Nasdaq rules require our Board of Directors to make an affirmative determination as to the independence of each director. Consistent with these rules, our Board of Directors undertook its annual review of director independence on March 29, 2011. During the review, our Board of Directors considered relationships and transactions during 2011 and during the past three fiscal years between each director or any member of his immediate family, on the one hand, and our company and our subsidiaries and affiliates, on the other hand. The purpose of this review was to determine whether any such relationships or transactions were inconsistent with a determination that the director is independent. Based on this review, our Board of Directors determined that Kevin Cameron, Joseph Feczko, M.D., Wyche Fowler, Jr., Jack Kaye and Michael Tarnok are independent under the criteria established by Nasdaq and by our Board of Directors. Our independent directors met two times during 2010 in sessions in which only the independent directors during that period participated.

The following biographies set forth the names of our director nominees, their ages, the year in which they first became directors, their positions with us, their principal occupations and employers for at least the past five years, any other directorships held by them during the past five years in companies that are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, or any company registered as an investment company under

the Investment Company Act of 1940, as well as additional information, all of which we believe sets forth each director nominee's qualifications to serve on the Board of Directors. There is no family relationship between and among any of our executive officers or directors. There are no arrangements or understandings between any of our executive officers or directors and any other person pursuant to which any of them are elected as an officer or director.

Michael P. Tarnok, 56, has served on our Board of Directors (the Board) since September 2007, and as Chairman of the Board since June 2009. Mr. Tarnok served as our interim chief executive officer from April 2009 to May 2009. A seasoned finance and operational executive, Mr. Tarnok joined the Board with

TABLE OF CONTENTS

extensive pharmaceutical industry experience in a wide range of functional areas. Mr. Tarnok spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director – US Manufacturing, and from 2000-2007, served as Senior Vice President, Finance in Pfizer’s U.S. Pharmaceuticals Division. In this position, Mr. Tarnok handled all finance responsibilities for the division, including contracting, trade management, forecasting of significant product launches and Sarbanes-Oxley compliance. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America. Mr. Tarnok earned an M.B.A. in Marketing from New York University and B.S. in Accounting from St. John’s University.

Ron Bentsur, 45, has served as our Chief Executive Officer since May 20, 2009, and has served on our Board of Directors since June 16, 2009. Prior to joining Keryx, Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals, Inc. (XTL), a position he held from January 2006 until April 2009. Prior to his tenure at XTL, Mr. Bentsur was with Keryx from 2000 – 2006, serving as our Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr. Bentsur worked as an investment banker in New York City, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a B.A. in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA, Magna Cum Laude, from New York University’s Stern Graduate School of Business.

Kevin J. Cameron, 42, has served on our Board of Directors since April 2007. Mr. Cameron has more than ten years of corporate governance experience. In 2003, Mr. Cameron co-founded Glass Lewis & Company, a leading independent research firm focused on issues of corporate governance. He currently serves as a member of the Policy Advisory Board of Glass Lewis. Mr. Cameron also serves on the board of ReddyIce Holdings, Inc. Mr. Cameron earned a law degree from the University of Chicago and an undergraduate degree from McGill University.

Joseph Feczko, M.D., 62, has served on our Board of Directors since July 16, 2010. Dr. Feczko is a seasoned pharmaceutical executive, with broad industry experience across the spectrum of medical, regulatory and operational affairs. Dr. Feczko was, until his retirement in May 2009, Senior Vice President and Chief Medical Officer (CMO) of Pfizer Inc. and member of the Executive Leadership Team with global responsibilities for all aspects of the company’s medical, regulatory and safety activities. Dr. Feczko served Pfizer in both New York and the United Kingdom since 1982, where he held positions of increasing responsibility in clinical research and regulatory affairs and safety, culminating in the role of Chief Medical Officer. Dr. Feczko is board-certified in Internal Medicine and Infectious Diseases. He has a B.Sc. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine. Dr. Feczko also serves on the board of directors of the Accordia Global Health Foundation and the Technical Expert Committee for Trachoma on the International Trachoma Initiative of the Task Force for Global Health, and is also a member of the governing board of the Technology Strategy Board of the United Kingdom. Dr. Feczko also serves as chairman of the board of directors of Cardoz Pharmaceuticals AB (Stockholm, Sweden) and a member of the Supervisory Board of Amsterdam Molecular Therapeutics based in The Netherlands.

Wyche Fowler, Jr., 70, has served on our Board of Directors since November 2006. Senator Fowler served for 16 years in the United States Congress representing the state of Georgia, including service in the United States Senate from 1987 to 1993. Following his service as a Senator, Senator Fowler served as the U.S. Ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. He received his B.A. in English from Davidson College, a J.D. from Emory University and honorary degrees from Hofstra University, Davidson College and Morris Brown College. Prior to his election to Congress, he practiced law in Atlanta, Georgia for eight years. He is currently engaged in an international business and law practice and serves as Chairman of the Board of the Middle East Institute, a non-profit research foundation in Washington, D.C. Mr. Fowler also serves on the board of directors of Shubert Theaters, the Shubert Foundation, Brandywine Realty Trust and ZIOPHARM Oncology, Inc.

TABLE OF CONTENTS

Jack Kaye, 67, has served on our Board of Directors since September 2006. Mr. Kaye began his career at Deloitte & Touche, LLP, an international accounting, tax and consulting firm, in 1970, and was a partner in the firm from 1978 until May 2006, when he retired. At Deloitte, Mr. Kaye was responsible for serving a diverse client base of public and private, global and domestic, companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/Sarbanes-Oxley issues. In addition, he has served as Deloitte's Tri-state liaison with the banking and finance community and assisted clients with numerous merger and acquisition transactions. Prior to retiring, Mr. Kaye served as Partner-in-Charge of Deloitte's Tri-State Core Client practice, a position he held for more than twenty years. Mr. Kaye previously served on the board of directors of Tongli Pharmaceuticals (USA), Inc., a China-based pharmaceutical company and Balboa Biosciences, Inc., a privately held biotech company. Mr. Kaye earned a B.B.A. from Baruch College and is a Certified Public Accountant.

During 2010, our Board of Directors held ten meetings. During 2010, each incumbent director standing for election attended at least 75% of the meetings of the Board of Directors and the meetings of those committees on which each incumbent director served, in each case during the period that such person was a director. The permanent committees established by our Board of Directors are the Audit Committee and the Compensation Committee, descriptions of which are set forth in more detail below. Our directors are expected to attend each Annual Meeting of Stockholders, and it is our expectation that all of the directors standing for election will attend this year's Annual Meeting. Last year, all of our directors attended the 2010 Annual Meeting of Stockholders, except for Joseph Feczko, M.D., who was appointed as a director subsequent to the 2010 Annual Meeting of Stockholders.

Communicating with the Board of Directors

Our Board of Directors has established a process by which stockholders can send communications to the Board of Directors. You may communicate with the Board of Directors as a group, or to specific directors, by writing to James F. Oliviero, our Corporate Secretary, at our offices located at 750 Lexington Avenue, New York, New York 10022.

The Corporate Secretary will review all such correspondence and regularly forward to the Board of Directors a summary of all correspondence and copies of all correspondence that, in the opinion of the Corporate Secretary, deals with the functions of the Board of Directors or committees thereof or that he otherwise determines requires their attention. Directors may at any time review a log of all correspondence we receive that is addressed to members of our Board of Directors and request copies of any such correspondence. Concerns relating to accounting, internal controls, or auditing matters may be communicated in this manner, or may be submitted on an anonymous basis via e-mail at info@keryx.com. These concerns will be immediately brought to the attention of our Audit Committee and handled in accordance with procedures established by our Audit Committee.

Audit Committee

The Audit Committee currently consists of Jack Kaye, Kevin Cameron, and Wyche Fowler, Jr.

The Audit Committee held four meetings during the fiscal year ended December 31, 2010. The duties and responsibilities of the Audit Committee are set forth in the Amended and Restated Charter of the Audit Committee which was recently reviewed by our Audit Committee. Our Audit Committee determined that no revisions needed to be made to the charter at this time. A copy of the Amended and Restated Charter of the Audit Committee is available on our website, located at www.keryx.com. Among other things, the duties and responsibilities of the Audit Committee include reviewing and monitoring our financial statements and internal accounting procedures, the selection of our independent registered public accounting firm and consulting with and reviewing the services provided by our independent registered public accounting firm. Our Audit Committee has sole discretion over the retention,

compensation, evaluation and oversight of our independent registered public accounting firm.

The SEC and Nasdaq have established rules and regulations regarding the composition of audit committees and the qualifications of audit committee members. Our Board of Directors has examined the composition of our Audit Committee and the qualifications of our Audit Committee members in light of the current rules and regulations governing audit committees. Based upon this examination, our Board of

TABLE OF CONTENTS

Directors has determined that each member of our Audit Committee is independent and is otherwise qualified to be a member of our Audit Committee in accordance with the rules of the SEC and Nasdaq.

Additionally, the SEC requires that at least one member of the Audit Committee have a heightened level of financial and accounting sophistication. Such a person is known as the audit committee financial expert under the SEC's rules. Our Board of Directors has determined that Mr. Kaye is an audit committee financial expert, as the SEC defines that term, and is an independent member of our Board of Directors and our Audit Committee. Please see Mr. Kaye's biography on page 6 for a description of his relevant experience.

The report of the Audit Committee can be found on page 11 of this proxy statement.

Compensation Committee

The Compensation Committee held two meetings during the fiscal year ended December 31, 2010. The Compensation Committee currently consists of Kevin Cameron, Wyche Fowler, Jr. and Michael Tarnok. The duties and responsibilities of the Compensation Committee are set forth in the Charter of the Compensation Committee. A copy of the Charter of the Compensation Committee is available on our website, located at www.keryx.com. As discussed in its charter, among other things, the duties and responsibilities of the Compensation Committee include evaluating the performance of the Chief Executive Officer and our other executive officers, determining the overall compensation of the Chief Executive Officer and our other executive officers and administering all executive compensation programs, including, but not limited to, our incentive and equity-based plans. The Compensation Committee evaluates the performance of the Chief Executive Officer and our other executive officers on an annual basis and reviews and approves on an annual basis all compensation programs and awards relating to such officers. The Compensation Committee applies discretion in the determination of individual executive compensation packages to ensure compliance with the Company's compensation philosophy. The Chief Executive Officer makes recommendations to the Compensation Committee with respect to the compensation packages for officers other than himself. The Compensation Committee may delegate its authority to grant awards to certain employees, and within specified parameters under the Company's 2007 Incentive Plan, to a special committee consisting of one or more directors who may but need not be officers of the Company. As of April 26, 2011, however, the Compensation Committee had not delegated any such authority. The Compensation Committee has engaged a compensation consultant to conduct a review of our executive compensation programs in 2011. The Committee did not engage a compensation consultant in 2010.

Nasdaq has established rules and regulations regarding the composition of compensation committees and the qualifications of compensation committee members. Our Board of Directors has examined the composition of our Compensation Committee and the qualifications of our Compensation Committee members in light of the current rules and regulations governing compensation committees. Based upon this examination, our Board of Directors has determined that each member of our Compensation Committee is independent and is otherwise qualified to be a member of our Compensation Committee in accordance with such rules.

The report of the Compensation Committee can be found on page 18 of this proxy statement.

Nominating Process

We do not currently have a nominating committee or any other committee serving a similar function. Director nominations are approved by a vote of a majority of our independent directors as required under the Nasdaq rules and regulations. Although we do not have a written charter in place to select director nominees, our Board of Directors has

adopted resolutions regarding the director nomination process. Our policy describing our director nomination process is available on our website, located at *www.keryx.com*. We believe that the current process in place functions to select director nominees who will be valuable members of our Board of Directors.

Our independent directors identify potential nominees to serve as directors through a variety of business contacts, including current executive officers, directors, community leaders and stockholders. The independent directors may, to the extent they deem appropriate, retain a professional search firm and other advisors to identify potential nominees.

TABLE OF CONTENTS

Our independent directors will also consider candidates recommended by stockholders for nomination to our Board of Directors. A stockholder who wishes to recommend a candidate for nomination to our Board of Directors must submit such recommendation to our Corporate Secretary, James F. Oliviero, at our offices located at 750 Lexington Avenue, New York, New York 10022. Any recommendation must be received not less than 60 calendar days nor more than 90 calendar days before the anniversary date of the previous year's annual meeting. All stockholder recommendations of candidates for nomination for election to our Board of Directors must be in writing and must set forth the following:

(i) the candidate's name, age, business address, and other contact information, (ii) the number of shares of Keryx common stock beneficially owned by the candidate, (iii) a complete description of the candidate's qualifications, experience, background and affiliations, as would be required to be disclosed in the proxy statement pursuant to Schedule 14A under the Exchange Act, (iv) a sworn or certified statement by the candidate in which he or she consents to being named in the proxy statement as a nominee and to serve as director if elected, and (v) the name and address of the stockholder(s) of record making such a recommendation.

We believe that our Board of Directors as a whole should encompass a range of talent, skill, and expertise enabling it to provide sound guidance with respect to our operations and interests. Our independent directors evaluate all candidates to our Board of Directors by reviewing their biographical information and qualifications. If the independent directors determine that a candidate is qualified to serve on our Board of Directors, such candidate is interviewed by at least one of the independent directors and our Chief Executive Officer. Members of the Board of Directors also have an opportunity to interview qualified candidates. The independent directors then determine, based on the background information and the information obtained in the interviews, whether to recommend to the Board of Directors that the candidate be nominated for approval by the stockholders to fill a directorship. With respect to an incumbent director whom the independent directors are considering as a potential nominee for re-election, the independent directors review and consider the incumbent director's service during his or her term, including the number of meetings attended, level of participation, and overall contribution to the Board of Directors. The manner in which the independent directors evaluate a potential nominee will not differ based on whether the candidate is recommended by our directors or stockholders.

We consider the following qualifications, among others, when making a determination as to whether a person should be nominated to our Board of Directors: the independence of the director nominee; the nominee's character and integrity; financial literacy; level of education and business experience, including experience relating to biopharmaceutical companies; whether the nominee has sufficient time to devote to our Board of Directors; and the nominee's commitment to represent the long-term interests of our stockholders. We review candidates in the context of the current composition of the Board of Directors and the evolving needs of our business. We believe that each of the current members of our Board of Directors (who are also our director nominees) has the requisite business, biopharmaceutical, financial or managerial experience to serve as a member of the Board of Directors, as described above in their biographies under the heading Our Board of Directors. We also believe that each of the current members of our Board of Directors has other key attributes that are important to an effective board, including integrity, high ethical standards, sound judgment, analytical skills, and the commitment to devote significant time and energy to service on the Board of Directors and its committees.

We do not have a formal policy in place with regard to the consideration of diversity in considering candidates for our Board of Directors, but the Board of Directors strives to nominate candidates with a variety of complementary skills so that, as a group, the Board of Directors will possess the appropriate talent, skills and expertise to oversee our business.

Code of Ethics

We have adopted a Code of Conduct and Ethics, or the Code, that applies to all of our directors and employees, including our principal executive officer and principal financial officer. The Code includes guidelines dealing with the ethical handling of conflicts of interest, compliance with federal and state laws, financial reporting, and our proprietary information. The Code also contains procedures for dealing with and reporting violations of the Code. We have posted our Code of Conduct and Ethics on our website, located at www.keryx.com.

8

TABLE OF CONTENTS

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FEES AND OTHER MATTERS

UHY LLP, the independent registered public accounting firm that audited our financial statements for the years ended December 31, 2010, and December 31, 2009 has served as our independent registered public accounting firm since 2009. UHY LLP leases all its personnel, who work under the control of UHY LLP partners, from wholly-owned subsidiaries of UHY Advisors, Inc. in an alternative practice structure (UHY LLP and UHY Advisors, Inc. collectively referred to as UHY). We expect a representative of UHY LLP to be present at the Annual Meeting. The representative will have an opportunity to make a statement and will be available to answer your questions.

Our Board of Directors has asked the stockholders to ratify the selection of UHY LLP as our independent registered public accounting firm. See Proposal Two: Ratification of Appointment of UHY LLP as Our Independent Registered Public Accounting Firm on page 34 of this proxy statement. The Audit Committee has reviewed the fees described below and concluded that the payment of such fees is compatible with maintaining UHY LLP's independence. All proposed engagements of UHY LLP, whether for audit services, audit-related services, tax services, or permissible non-audit services, were pre-approved by our Audit Committee.

Between 1996 and 2009, KPMG LLP served as our independent registered public accounting firm. On April 3, 2009, the Audit Committee of our Board of Directors approved the dismissal of KPMG LLP as our independent registered public accounting firm, and as of April 14, 2009, approved the retention of UHY LLP to audit our financial statements for the year ended December 31, 2009.

Audit Fees

For the fiscal years ended December 31, 2010 and December 31, 2009, UHY LLP billed us an aggregate of approximately \$157,050 and \$113,800, respectively, in fees for the professional services rendered in connection with the audits of our annual financial statements included in our Annual Reports on Form 10-K for those two fiscal years, the review of our financial statements included in our Quarterly Reports on Form 10-Q during those two fiscal years, and our registration statement filings.

Audit-Related Fees

During the fiscal years ended December 31, 2010 and December 31, 2009, we were not billed by UHY LLP for any fees for audit-related services reasonably related to the performance of the audits and reviews for those two fiscal years, in addition to the fees described above under the heading Audit Fees.

Tax Fees

During the fiscal years ended December 31, 2010 and December 31, 2009, UHY billed us an aggregate of approximately \$41,750 and \$23,300, respectively, for professional services rendered for tax compliance, tax advice, and tax planning services. These professional services consisted of general consultation from time to time regarding compliance with and planning for federal, state, local, and international tax matters, as well as services related to New York City's examination of our tax returns, which was completed in 2010.

All Other Fees

During the fiscal years ended December 31, 2010 and December 31, 2009, we were not billed by UHY for any fees for services, other than those described above, rendered to us and our affiliates for those two fiscal years.

Pre-Approval of Services

Our Audit Committee has established a policy setting forth the procedures under which services provided by our independent registered public accounting firm will be pre-approved by our Audit Committee. The potential services that might be provided by our independent registered public accounting firm fall into two categories:

Services that are permitted, including the audit of our annual financial statements, the review of our quarterly financial statements, related attestations, benefit plan audits and similar audit reports, financial and other due diligence on acquisitions, and federal, state, and non-US tax services; and

9

TABLE OF CONTENTS

Services that may be permitted, subject to individual pre-approval, including compliance and internal-control reviews, indirect tax services such as transfer pricing and customs and duties, and forensic auditing.

Services that our independent registered public accounting firm may not legally provide include such services as bookkeeping, certain human resources services, internal audit outsourcing, and investment or investment banking advice.

All proposed engagements of our independent registered public accounting firm, whether for audit services or permissible non-audit services, are pre-approved by the Audit Committee. We jointly prepare a schedule with our independent registered public accounting firm that outlines services that we reasonably expect we will need from our independent registered public accounting firm, and categorize them according to the classifications described above.

Each service identified is reviewed and approved or rejected by the Audit Committee.

10

TABLE OF CONTENTS

REPORT OF THE AUDIT COMMITTEE

In monitoring the preparation of our financial statements, the Audit Committee met with both management and UHY LLP, our independent registered public accounting firm for the year ended December 31, 2010, to review and discuss all financial statements prior to their issuance and to discuss any and all significant accounting issues. Management and our independent registered public accounting firm advised the Audit Committee that each of the financial statements were prepared in accordance with generally accepted accounting principles. The Audit Committee's review included a discussion of the matters required to be discussed pursuant to the Statement on Auditing Standards No. 61, Communication with Audit Committees, as amended, (Codification of Statements on Auditing Standards, AU Section 380) as adopted by the Public Company Accounting Oversight Board (PCAOB) in Rule 3200T, or SAS 61. SAS 61 requires our independent registered public accounting firm to discuss with the Audit Committee, among other things, the following:

Methods used to account for significant or unusual transactions;

The effect of any accounting policies in controversial or emerging areas for which there is a lack of authoritative guidance or consensus;

The process used by management to formulate sensitive accounting estimates and the basis for the independent registered public accounting firm's conclusion regarding the reasonableness of any such estimates; and

Any disagreements with management over the application of accounting principles, the basis for management's accounting estimates and the disclosures necessary in the financial statements.

The Audit Committee has discussed the independence of UHY LLP, our independent registered public accounting firm for the year ended December 31, 2010, including the written disclosures made by UHY LLP to the Audit Committee, as required PCAOB Rule 3526, Communication with Audit Committees Concerning Independence.

PCAOB Rule 3526 requires the independent registered public accounting firm to (i) disclose in writing all relationships that, in the independent registered public accounting firm's professional opinion, may reasonably be thought to bear on independence, (ii) confirm their perceived independence, and (iii) engage in a discussion of independence with the Audit Committee.

Finally, the Audit Committee continues to monitor the scope and adequacy of our internal controls and other procedures, including any and all proposals for adequate staffing and for strengthening internal procedures and controls where appropriate and necessary.

On the basis of these reviews and discussions, the Audit Committee recommended to the Board of Directors that it approve the inclusion of our audited financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010, for filing with the SEC.

The Audit Committee reviewed its written charter previously adopted by our Board of Directors. Following this review, the Audit Committee determined that no changes needed to be made with respect to the Audit Committee charter at this time.

By the Audit Committee of the Board of Directors

Jack Kaye, Chairperson
Kevin J. Cameron
Wyche Fowler, Jr.

Dated March 3, 2011

TABLE OF CONTENTS

OUR EXECUTIVE OFFICERS

Executive Officers

Our current executive officers are as follows:

Name	Age	Position
Ron Bentsur	45	Chief Executive Officer and Director
James F. Oliviero	35	Chief Financial Officer, Treasurer and Corporate Secretary

No executive officer is related by blood, marriage or adoption to any other director or executive officer. The biography of Mr. Bentsur is presented in connection with Corporate Governance beginning on page 4 of this proxy statement.

James F. Oliviero, 35, has served as our Chief Financial Officer since April 2009 and previously served as our Vice President, Finance since March 2008. From May 2003 until March 2008, Mr. Oliviero served as Keryx's Controller, where he was involved in all capital raising, licensing and acquisition transactions. Since joining Keryx, Mr. Oliviero has also been in charge of leading Keryx's compliance with SEC rules and regulations and other corporate governance matters. From August 1999 until May 2003, Mr. Oliviero served as Director of Finance for ACCESS Oncology, Inc., a privately-held biotechnology company. From July 1997 to August 1999, Mr. Oliviero was an investment banker at ING Barings Furman Selz in New York City, where he worked on various mergers and acquisitions and equity and debt transactions. Mr. Oliviero holds a B.B.A. in Finance with Highest Distinction from Emory University's Goizueta Business School.

TABLE OF CONTENTS

COMPENSATION DISCUSSION AND ANALYSIS

In the paragraphs that follow, we give an overview and analysis of our compensation program and policies, the material compensation decisions we have made under those programs and policies with respect to our executive officers, and the material factors that we considered in making those decisions. Later in this proxy statement under the heading Executive Compensation, you will find a series of tables containing specific information about the compensation earned or paid in 2010 to the following individuals, whom we refer to as our named executive officers, or NEOs:

Ron Bentsur, our Chief Executive Officer; and
James F. Oliviero, our Chief Financial Officer, Treasurer and Corporate Secretary.

Compensation Philosophy and Objectives

Our compensation programs are designed to motivate our employees to work toward achievement of our corporate mission to create long-term sustained stockholder value by acquiring, developing and commercializing medically important pharmaceutical products for the treatment of cancer and renal disease. Attaining our key business and strategic goals depends on attracting, retaining and motivating quality employees in an exceptionally competitive environment. Our industry is highly scientific, regulated, scrutinized and dynamic, and as a result, we require employees that are highly educated, dedicated and experienced.

The driving philosophy and objectives behind our executive compensation programs are:

to attract, retain, motivate and reward outstanding employees;
to align employees' interests with those of our stockholders by creating a strong focus on stock ownership and basing pay on performance measures that drive long-term stockholder value;
to incentivize our employees to achieve our business goals; and
to reflect our pay for performance culture.

Determining Executive Compensation

Role of the Compensation Committee

The Compensation Committee oversees our executive compensation programs, including approving incentive programs, granting equity awards, and determining appropriate levels of compensation for our executives. Information about the Compensation Committee and its composition and responsibilities can be found on page 7 under the caption Compensation Committee. The Compensation Committee did not engage a compensation consultant in 2010 and did not benchmark 2010 executive pay against a peer group. However, the Committee has engaged a compensation consultant to conduct a review of our executive compensation programs in 2011.

Role of the Executives

Our Chief Executive Officer develops recommendations regarding individual compensation levels for executives other than himself based upon a subjective consideration of each executive's individual performance during the prior year and overall trends in the marketplace. In addition, each year, management delivers to the Compensation Committee a set of proposed corporate goals and objectives that management believes are essential to the achievement of the Company's mission and long-term goals and objectives. These recommendations and proposed goals and objectives are reviewed, modified if deemed appropriate, and approved by the Compensation Committee.

TABLE OF CONTENTS

Elements of Compensation

Our executive compensation program consists of the following components:

Compensation Element	<i>Purpose</i>
Base salary	Base salary represents the fixed portion of an executive's annual compensation and is intended to recognize the executive's value to the Company based on skills and experience relative to the responsibilities of his position.
Annual cash incentive awards	Annual cash incentive awards represent the portion of an executive's compensation that is intended to vary as a direct reflection of Company and individual performance for the year. Mr. Bentsur's maximum annual incentive award was equal to 75% of his base salary, per the terms of his employment agreement. Mr. Oliviero's annual incentive award was determined in connection with the Company's annual incentive bonus pool, as described below.
Long-term equity awards	Long-term equity awards are intended to reward performance over a multi-year period, link the interests of executives to those of the stockholders, and encourage retention. Restricted stock and stock options generally are issued based upon achievement of corporate goals and objectives in the prior year. In addition, Mr. Bentsur is eligible to receive grants of restricted stock pursuant to the performance thresholds provided in his employment agreement, with additional time-based vesting requirements.
Health and welfare plans and retirement plan	These benefits are intended to provide competitive levels of medical and disability coverage, and retirement benefits under our 401(k) plan. Our executives participate in the same programs offered to all of our eligible employees.

No specific formula is used in regard to the allocation of the various elements within our executive compensation program. The Compensation Committee retains the discretion to reduce or eliminate the payment that otherwise might be payable to our executives based upon unforeseen events occurring during the year or its assessment of the Company's or our executive's performance in general.

In order to maximize the incentive effect of our compensation program, we have structured our performance-based compensation to involve a mix of value opportunities and performance measures.

Our annual cash incentive awards and our annual equity awards are based partially upon the Company's performance against pre-set corporate goals and objectives and partially upon the Compensation Committee's assessment of each individual executive's contribution to the Company's performance.

The value of our equity awards (stock options and restricted stock awards) is tied to our stock price, in alignment with our stockholders.

In addition to the compensation components described above, our Chief Executive Officer has an employment agreement that provides for severance benefits in certain circumstances.

TABLE OF CONTENTS

2010 Executive Compensation

2010 Corporate Performance Goals

Our 2010 annual incentive awards were based upon the achievement of corporate performance goals, which included a combination of clinical and regulatory goals related to our products as well as other corporate goals, and were achieved at an aggregate level of 70%, as well as a consideration of individual performance. The corporate performance goals and objectives used to determine annual incentive awards were as follows:

Various goals related to Zerenex studies 30% maximum potential weighting (22.5% achieved);
Various goals related to Perifosine studies and designations 27.5% maximum potential weighting (22.5% achieved);
Progress in business and corporate development efforts 25% maximum potential weighting (12.5% achieved); and
Stock price targets 17.5% maximum potential weighting (12.5% achieved).

The Compensation Committee considered performance against these goals in determining the amounts paid as annual incentive awards in 2010, as well as its subjective assessment of our executives' contributions to Company performance.

Base Salary

Mr. Bentsur's base salary for 2010 remained unchanged at \$300,000. On April 1, 2010, the Compensation Committee increased Mr. Oliviero's base salary increase by 10.4%. In making these determinations, the Compensation Committee considered a number of factors, including performance against corporate goals and objectives and individual performance, which was determined based upon subjective evaluations. In addition, the Compensation Committee recognized that, due to the financial condition of the Company at the time, it had not increased Mr. Oliviero's base salary upon his promotion to Chief Financial Officer in 2009.

Cash Incentive Awards

In 2010, Mr. Bentsur was eligible to earn an annual cash incentive of up to 75% of his base salary, per the terms of his employment agreement. Mr. Oliviero's annual incentive award was determined in connection with the Company's annual incentive bonus pool, as described below. Both executives' annual cash incentive awards were based upon the Company's performance against pre-established corporate goals and objectives and each executive's individual performance based upon subjective performance reviews. The actual amounts paid to the executives pursuant to their annual cash incentive awards are reported in the Summary Compensation Table as non-equity incentive plan compensation.

Mr. Bentsur's 2010 Annual Cash Incentive Award. As noted above, in 2010, Mr. Bentsur was eligible to earn an annual cash incentive of up to 75% of his base salary, per the terms of his employment agreement. Mr. Bentsur's annual cash incentive was based on achievement of the corporate goals and objectives (80% weighting), which was achieved at the 70% level, and on individual performance, based upon a subjective review by the Compensation Committee (20% weighting), which was achieved at the 100% level. In addition, based on its assessment of Mr. Bentsur's contribution to the Company's performance during 2010, the Compensation Committee used its discretion to increase Mr. Bentsur's award by \$4,000, resulting in a \$175,000 payment (against a maximum potential award of \$225,000).

Annual Cash Incentive Award Pool and Mr. Oliviero's 2010 Annual Cash Incentive Award. In 2010, our employees, other than Mr. Bentsur, were eligible for annual cash incentives based on an overall annual cash incentive award pool calculated as the sum of our employees' salaries (excluding Mr. Bentsur) multiplied by a percentage set by the

Compensation Committee for such year. In 2010, the percentage was set at 25.0%, resulting in a maximum cash incentive pay pool of \$484,970. For most of our employees, a component of their annual cash incentive is based on corporate goals and objectives and a component is based on individual performance. At the lowest level, employees only have an individual component. For 2010, following a 3.5% discretionary upward adjustment to the calculated award by the Compensation Committee, \$449,598 was distributed to employees under the annual cash incentive award pool, including Mr. Oliviero.

TABLE OF CONTENTS

Mr. Oliviero's maximum 2010 annual cash incentive was determined based upon the ratio of 40% of his base salary to the maximum amount available under the pool, or 21.9% of the maximum pool amount. His award was based on achievement of the corporate goals and objectives (70% weighting), which was achieved at the 70% level, and on individual performance, based upon a subjective review by the Chief Executive Officer and the Compensation Committee (30% weighting), which was achieved at the 100% level. In addition, based on its assessment of Mr. Oliviero's contribution to the Company's performance during 2010, the Compensation Committee used its discretion to increase Mr. Oliviero's award by \$22,260, resulting in a \$106,000 payment, which represented the maximum potential award.

Long-term Equity Incentive Awards

Mr. Bentsur. On May 20, 2009, Mr. Bentsur was granted an option to purchase 600,000 shares of our common stock, at an exercise price of \$0.35, which we refer to as the Initial Option Grant. The Initial Option Grant was issued as an inducement award for Mr. Bentsur to join our company in accordance with Nasdaq Marketplace Rule 5635(c)(4) and was not granted under our stockholder-approved incentive plan. The Initial Option Grant will vest in equal installments on each of the first four anniversaries of the grant date, conditioned upon Mr. Bentsur's continuing employment, and subject to other terms and conditions set forth in the award agreement. The Initial Option Grant will become fully-vested upon the occurrence of a change in control.

On January 2, 2010, Mr. Bentsur was granted an option to purchase 123,840 shares of our common stock, based upon our 2009 corporate goals and objectives, which were achieved at a 75% level, and a subjective consideration of Mr. Bentsur's individual performance during 2009.

In addition, Mr. Bentsur's employment agreement provides that he has the opportunity to receive certain restricted stock awards upon the achievement of performance milestones. On September 22, 2009, Mr. Bentsur received 100,000 shares of restricted stock upon the achievement of the first milestone (\$1.00 share price of our common stock based upon average closing price for a 120-day period), which we refer to as the Bentsur 1st Milestone Award. The restricted stock was scheduled to vest in equal installments over each of the first three anniversaries of the grant date provided that he remains employed by us during such vesting period, or immediately upon achievement of the Bentsur 2nd Milestone Award (as defined below).

On March 23, 2010, Mr. Bentsur was granted 250,000 shares of restricted stock upon achievement of the second milestone (\$2.50 share price of our common stock based upon average closing price for a 120-day period), which we refer to as the Bentsur 2nd Milestone Award. The restricted stock is scheduled to vest in equal installments over each of the first three anniversaries of the grant date, provided that he remains employed by us during such vesting period. Upon achievement of the second milestone, the 100,000 restricted shares previously granted to Mr. Bentsur for the Bentsur 1st Milestone Award were immediately vested, as described above.

Mr. Bentsur's employment agreement provides that he has the opportunity to receive the following additional milestone awards:

400,000 shares of restricted stock upon the first to occur of (a) our filing of an accepted new drug application (an NDA) with the U.S. Food and Drug Administration for Zerenex or Perifosine, or (b) our outlicensing of Zerenex or Perifosine in the U.S. to a third party, which we refer to as the Bentsur 3rd Milestone Award. Such restricted stock will vest in equal installments over each of the first three anniversaries of the grant date provided that Mr. Bentsur remains employed by us during such vesting period. The Bentsur 3rd Milestone Award may be achieved with respect to NDAs or qualifying outlicenses for multiple indications of the same product, but not for subsequent outlicenses of the product relating to an indication for which the milestone is met.

500,000 shares of restricted stock upon the first to occur of (a) our first commercial sale of Zerenex or Perifosine in the U.S. off an approved NDA, (b) our receipt of the first royalty upon the commercial sale of Zerenex or Perifosine in the U.S. by a partner to whom the Company has sold exclusive or non-exclusive commercial rights, or (c) our complete outlicensing of the entire product

16

TABLE OF CONTENTS

rights of Zerenex or Perifosine in the U.S., which we refer to as the Bentsur 4th Milestone Award. Such restricted stock will vest on the first anniversary of the grant date provided that he remains employed by us during such vesting period.

100,000 shares of restricted stock upon each event of our outlicensing Zerenex in a foreign market, other than Japan, resulting in a greater than \$10 million non-refundable cash payment to the Company with a gross deal value to the Company of at least \$50 million, which we refer to as the Bentsur 5th Milestone Award. Such restricted stock will vest in equal installments over each of the first three anniversaries of the date of grant provided he remains employed by us during such vesting period.

Annual Equity Award Pool and Mr. Oliviero. In 2010, our employees, other than Mr. Bentsur, were eligible for long-term equity awards based on an overall annual equity award pool of 393,831 shares, calculated based upon 0.575% of an adjusted fully-diluted shares outstanding figure (68,492,422). For 2010, each employee was allocated a portion of the annual equity award pool which represented such employee's maximum potential grant. For most of our employees, a component of their annual equity award is based on corporate goals and objectives and a component is based on individual performance. At the lowest level, employees only have an individual component. For 2010 (based upon performance over 2009), following a 7.4% discretionary upward adjustment to the calculated award by the Compensation Committee, 330,500 shares of restricted stock were granted to employees from the annual equity award pool, including a grant of 100,000 restricted shares to Mr. Oliviero, which vest as to 33.3% of the shares on the first anniversary of the grant date and as to 8.3% of the shares each quarter thereafter (all shares becoming fully vested by January 2, 2013).

For additional information regarding our named executive officers' stock grants, see the Summary Compensation Table, the Grants of Plan-Based Awards Table and the Outstanding Equity Awards at 2010 Fiscal Year End table. Awards based upon 2010 performance were granted on January 2, 2011. Pursuant to SEC rules, these awards will appear in next year's proxy statement.

Perquisites and Other Executive Benefits

We do not offer our NEOs any perquisites or other executive benefits.

Severance Benefits

We have an employment agreement with Mr. Bentsur that provides, among other things, benefits upon certain terminations of employment. We believe this agreement can be an important component of our effort to recruit and retain a chief executive officer, particularly for a company at our stage of development and in our relatively high-risk industry. For more information on Mr. Bentsur's employment agreement, see the Potential Payments upon Termination or Change-in-Control section beginning on page 22 of this proxy statement.

Tax and Accounting Considerations

All compensation is subject to federal, state and local taxes as ordinary income or capital gains as various tax jurisdictions provide. U.S. tax code Section 162(m) places a limit of \$1,000,000 on the amount of compensation that we may deduct in any one year with respect to any one of our named executive officers. However, qualifying performance-based compensation will not be subject to the deduction limit if certain requirements are met. The Compensation Committee anticipates that stock options granted under incentive plans qualify as performance-based compensation, while our time-vested restricted stock does not. In addition, in most years annual incentives for executives will qualify as performance-based compensation, but to maintain flexibility in compensating our

executives, the Compensation Committee reserves the right to use its judgment to authorize compensation payments that may be subject to the limit when the Compensation Committee believes that such payments are appropriate. For example, the Compensation Committee's discretionary adjustments to Mr. Bentsur and Mr. Oliviero's annual incentive awards for 2010 make those awards ineligible for exemption under Section 162(m). Accordingly, certain components of our executive compensation program are designed to be qualifying performance-based compensation under U.S. tax code Section 162(m) while others are not.

17

TABLE OF CONTENTS

Report of the Compensation Committee

The Compensation Committee of the Board of Directors has reviewed and discussed with management the Compensation Discussion and Analysis set forth above. Based on the review and discussions noted above, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement and incorporated by reference in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010, for filing with the SEC.

By the Compensation Committee of the Board of Directors

Kevin Cameron, Chairperson
Wyche Fowler, Jr.
Michael Tarnok

TABLE OF CONTENTS

RISK ASSESSMENT OF COMPENSATION PROGRAMS

The Compensation Committee has reviewed with management the design and operation of our incentive compensation arrangements for all employees, including executive officers, for the purpose of determining whether such programs might encourage inappropriate risk-taking that could have a material adverse effect on the Company.

Management compiled an inventory of all incentive compensation arrangements applicable to the Company's employees at all levels, which plans and arrangements were reviewed for the purpose of identifying any aspects of such programs that might encourage behaviors that could exacerbate business risks. In conducting this assessment, the Compensation Committee considered, among other things, the performance objectives used in connection with these incentive awards and the features of the Company's compensation program that are designed to mitigate compensation-related risk. The Compensation Committee concluded that any risks arising from the Company's compensation plans, policies and practices are not reasonably likely to have a material adverse effect on the Company.

TABLE OF CONTENTS**EXECUTIVE COMPENSATION****Summary Compensation Table**

The following table sets forth the cash and other compensation that we paid to our current named executive officers (NEOs) or that was otherwise earned by our NEOs for their services in all capacities during 2008, 2009 and 2010. For a description of the individual amounts indicated below, please see our Compensation Discussion and Analysis beginning on page 13 of this proxy statement.

Name and Principal Position	Year	Salary (\$)	Stock Awards (\$) ⁽¹⁾	Option Awards (\$) ⁽¹⁾	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total (\$)
Ron Bentsur	2010	300,000	710,000	251,829	175,000		1,436,829
Chief Executive Officer ⁽²⁾	2009	183,750	236,000	176,340	111,456	20,349 ⁽⁴⁾	727,895
James F. Oliviero	2010	258,750	250,000		106,000		614,750
Chief Financial Officer,	2009	240,000	11,500		100,000		351,500
Treasurer and Corporate Secretary ⁽³⁾	2008	240,000	109,200		25,500		374,700

Reflects the aggregate grant date fair value of stock and option awards granted by the Company as computed under FASB ASC Topic 718. The grant date fair value of the stock awards is based on the fair market value of the (1) underlying shares on the date of grant and does not take into account any estimated forfeitures. The assumptions made in the valuation of the option awards are contained in Note 11 to our consolidated financial statements for 2010, which are included in our Annual Report on Form 10-K for the fiscal year 2010.

(2) Mr. Bentsur was appointed our Chief Executive Officer on May 20, 2009.

(3) Mr. Oliviero was appointed as our principal financial and accounting officer on May 6, 2008. Mr. Oliviero became our Chief Financial Officer on April 23, 2009.

(4) Reflects payments for consulting services provided by Mr. Bentsur to us between March 19, 2009 and May 19, 2009, prior to becoming Chief Executive Officer.

Grants of Plan-Based Awards For Fiscal Year 2010

The following table below sets forth the individual grants of awards made to each of our NEOs during 2010. For a description of the individual amounts indicated below, please see our Compensation Discussion and Analysis beginning on page 13 of this proxy statement.

Represents target payout values for 2010 cash performance awards. Pursuant to his employment agreement, Mr. Bentsur was eligible to receive a target cash bonus of up to 75% of his base salary. At the Compensation Committee's discretion, payouts can be zero. The actual amount earned by each NEO in 2010 is reported under the Non-Equity Incentive Plan Compensation column in the Summary Compensation Table on page 20 of this proxy statement.

TABLE OF CONTENTS

- Reflects the aggregate grant date fair value of stock and option awards granted by the Company as computed under FASB ASC Topic 718. The grant date fair value of the stock awards is based on the fair market value of the
- (2) underlying shares on the date of grant and does not take into account any estimated forfeitures. The assumptions made in the valuation of the option awards are contained in Note 11 to our consolidated financial statements for 2010, which are included in our Annual Report on Form 10-K for the fiscal year 2010.
- (3) Award of time-vesting options and restricted stock to Mr. Bentsur and Mr. Oliviero, respectively, under the 2007 Incentive Plan, or the 2007 Plan.
- (4) Award of time-vesting restricted stock to Mr. Bentsur under the 2007 Plan pursuant to the terms of his employment agreement.

For a description of the vesting schedules of the equity awards, please see the table below. For a description of Mr. Bentsur's employment agreement please see page 21 of this proxy statement.

Employment Agreements

Employment Agreement with Mr. Bentsur. We entered into an employment agreement with Mr. Bentsur on September 14, 2009. The agreement terminates on May 20, 2012, provided, however, that Mr. Bentsur's opportunity to earn the milestone awards described in the Compensation Discussion and Analysis on pages 16 and 17 of this proxy statement will be effective until May 20, 2014, subject to certain early termination events. Under the employment agreement, Mr. Bentsur's base salary will be equal to \$300,000 per year, which may be increased from year to year or decreased in an amount up to 10% in the aggregate in the discretion of the Compensation Committee. Mr. Bentsur also is eligible to receive an annual bonus, not to exceed 75% of his base salary, if certain performance objectives agreed to by the Compensation Committee and Mr. Bentsur are met. Mr. Bentsur's employment agreement also entitles him to severance and other benefits in the event of certain terminations of employment, as described under "Potential Payments upon Termination or Change in Control" below.

Mr. Oliviero does not have an employment agreement.

Outstanding Equity Awards at 2010 Fiscal Year End

The following table provides information concerning equity awards that are outstanding as of December 31, 2010 for each of our NEOs.

Name	Option Awards				Stock Awards	
	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price (\$)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested (\$)
Mr. Bentsur	150,000 ⁽¹⁾	450,000 ⁽¹⁾	0.35	05/20/19	250,000 ⁽⁹⁾	1,145,000
		123,840 ⁽²⁾	2.50	01/02/20		
Mr. Oliviero	30,000 ⁽³⁾		4.59	01/02/14		
	25,000 ⁽⁴⁾		11.22	01/03/15		

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form DEF 14A

50,000	(5)			14.64	01/02/16		
50,000	(6)			14.64	01/02/16		
25,000	(7)			13.30	12/31/16		
13,500	(8)	4,500	(8)	8.56	12/30/17		
						93,334	(10) 427,470
						28,125	(11) 125,000
						100,000	(12) 458,000

(1) Stock options awarded to executive on May 20, 2009, under the 2009 CEO Incentive Plan. The stock options vest as to 150,000 of the options on each of May 20, 2010, May 20, 2011, May 20, 2012 and May 20, 2013.

21

TABLE OF CONTENTS

- (2) Stock options awarded to executive on January 2, 2010, under the 2007 Plan. The stock options vest as to 41,280 of the options on each of January 2, 2011, January 2, 2012, and January 2, 2013.
Stock options awarded to the executive on January 2, 2004, under the 2000 Stock Option Plan (the 2000 Plan). The
- (3) stock options vested as to 7,500 of the options on January 2, 2005, and the remaining options vested in equal installments on a quarterly basis through January 2, 2008.
Stock options awarded to the executive on January 3, 2005, under the 2004 Long-Term Incentive Plan (the 2004
- (4) Plan). The stock options vested as to 6,256 options on January 3, 2006, and the remaining options vested in equal installments on a quarterly basis through January 3, 2009.
Stock options awarded to the executive on January 2, 2006, under the 2004 Plan. The stock options vested as to
- (5) 12,500 options on January 2, 2007, and the remaining options vested in equal installments on a quarterly basis through January 2, 2010.
Stock options awarded to the executive on January 2, 2006, under the 2004 Plan. The stock options vested in 2006
- (6) due to the achievement of a certain financial milestone.
Stock options awarded to the executive on December 31, 2006, under the 2004 Plan. The stock options vested as to
- (7) 6,256 options on December 31, 2007, and the remaining options vested in equal installments on a quarterly basis through December 31, 2010.
Stock options awarded to the executive on December 30, 2007, under the 2007 Plan. The stock options vested as to
- (8) 4,500 options on December 30, 2008, and the remaining options vest in equal installments on a quarterly basis through December 30, 2011.
- (9) Restricted stock granted to the executive on March 23, 2010, under the 2007 Plan, which vest as to 83,333 shares on March 23, 2011, 83,334 shares on March 23, 2012 and 83,333 shares on March 23, 2013.
- (10) Restricted stock granted to the executive on August 14, 2008, under the 2007 Plan, which vest as to 93,334 shares on June 5, 2011.
- (11) Restricted stock granted to the executive on January 2, 2009, under the 2007 Plan, which vest as to 3,125 shares on January 2, 2011, and the remaining vest in equal installments on a quarterly basis through January 2, 2013.
- (12) Restricted stock granted to the executive on January 2, 2010, under the 2007 Plan, which vest as to 33,333 shares on January 2, 2011, and the remaining vest in equal installments on a quarterly basis through January 2, 2013.

Option Exercises and Stock Vested in Fiscal Year 2010

The following table provides information regarding the number of shares acquired upon exercise of stock options and vesting of shares for our NEOs during 2010.

Name	Option Awards		Stock Awards	
	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise (\$)	Number of Shares Acquired on Vesting (#)	Value Realized on Vesting (\$) ⁽¹⁾
Mr. Bentsur			100,000	284,000
Mr. Oliviero	31,667	130,545	115,208	513,936

- (1) Represents the aggregate value of restricted stock vesting in 2010, based upon the fair market value of our common stock on the applicable vesting date.

Potential Payments upon Termination or Change in Control

We have an employment agreement with Mr. Bentsur that provides certain compensation and benefits in the event of the termination of his employment under certain conditions. In addition, we have incentive plans that will require us to provide compensation and benefits to our named executive officers in the event of a termination of employment following a change in control of our Company. Pursuant to the terms of the 2004 Plan, upon the occurrence of a change in control, any awards outstanding under such plan will become fully-vested. Pursuant to the terms of the 2007 Plan, upon the occurrence of a change in control of the Company in which awards are not assumed by the surviving entity or otherwise equitably converted or substituted in connection with the change in control, all outstanding awards under such plan will become fully vested. The

TABLE OF CONTENTS

2007 Plan also provides that, with respect to awards assumed by the surviving entity or otherwise equitably converted or substituted in connection with a change in control, if within two years after the effective date of the change in control, a participant's employment is terminated without Cause or the participant resigns for Good Reason, then all outstanding awards under such plan will become fully-vested. For purposes of the 2007 Plan, Good Reason generally means (i) a material diminution in the participant's duties, or the assignment to the participant of duties materially inconsistent with his or her authority, responsibilities and reporting requirements; or (ii) a material breach by the Company of its obligations to the participant under any written employment agreement or arrangement. For purposes of the 2007 Plan, Cause generally means (i) a material breach of the terms of the participant's restrictive covenants with the Company; (b) a material breach by the participant of any provision of his or her employment arrangement; (c) the habitual neglect or gross failure by the participant to adequately perform his or her duties; (d) any act of moral turpitude or criminal action connected to the participant's employment with the Company; or (e) the participant's repetitive refusal to comply with, or his or her violation of lawful instructions of, the Chief Executive Officer, Chief Financial Officer or the Board of Directors.

Ron Bentsur

The table below summarizes the value of potential payments and benefits that Mr. Bentsur would receive if his employment was terminated on December 31, 2010 under the circumstances shown, or if a change in control of the Company occurred on December 31, 2010. The table excludes amounts that would be paid in the normal course of continued employment, such as accrued but unpaid salary. Actual amounts to be paid can only be determined at the time of such termination of service.

Type of Payment	Termination Other Than For Cause; Resignation For Good Reason	Death or Disability; Termination of Employment in Connection With Expiration of Employment Period	Termination Following a Change in Control
	(\$)	(\$)	(\$)
Cash Severance	150,000		
Value of Accelerated Stock Options and Restricted Stock ⁽¹⁾	1,145,000	1,145,000	7,428,087
Total	1,295,000	1,145,000	7,428,087

Represents the fair market value of shares underlying outstanding stock options and restricted shares that would be vested upon the event, based on \$4.58 closing price as of December 31, 2010, the last trading day of the most (1) recently completed fiscal year, less the exercise price of the stock option. For purposes of this calculation, outstanding options having an exercise price equal to or more than the closing price of our common stock on such date have a value of \$0.

Termination Other than for Cause; Termination for Good Reason. If we terminate Mr. Bentsur for any reason other than for Cause or disability, or if he terminates his employment for Good Reason, then he is entitled to the following benefits:

a lump sum cash severance payment equal to 50% of his then-current base salary;
any vested portion of the Initial Option Grant will remain exercisable for a period of one year;
any outstanding shares of restricted stock granted to Mr. Bentsur as a milestone award by reason of the achievement of a milestone (as described earlier in this proxy statement) (the Earned Milestone Awards) prior to the date of termination will become fully vested and non-forfeitable as of the date of termination; and
his opportunity to earn milestone awards with respect to any milestone condition which has not been met as of the date of termination (the Unearned Milestone Opportunity) will continue for a period of three months after the date of termination and, to the extent that a milestone is achieved during

23

TABLE OF CONTENTS

such three-month period, the stock relating to such milestone will be issued to Mr. Bentsur as fully-vested shares, rather than restricted stock, or, in our sole discretion, we may pay Mr. Bentsur an amount in cash equal to the value of such shares.

The employment agreement also provides that if any payments or benefits would be subject to the excise tax imposed on parachute payments under Section 4999 of the Internal Revenue Code, the payments will be limited to the maximum amount that could be paid without triggering the excise tax, provided that such cut-back would produce a greater net benefit to Mr. Bentsur than if he had paid the excise tax.

Cause generally means the executive s: (i) conviction of, pleading guilty to, or confession to a felony or any crime involving any act of dishonesty, fraud, misappropriation or embezzlement; (ii) misconduct or gross negligence in connection with the performance of his duties; (iii) engaging in any fraudulent, disloyal or unprofessional conduct which is, or is likely to be, injurious to the Company, its financial condition, or its reputation; (iv) failure to perform his duties with the Company; (v) failure to meet agreed-upon, written performance standards; or (vi) breach of the covenants in the agreement, or material breach of any other provisions of this Agreement. Good Reason generally means (i) a reduction in his base salary of more than 10% in the aggregate (i.e., in excess of \$30,000); (ii) a material diminution in his authority, duties, or responsibilities; (iii) a requirement that he report to a corporate officer or employee instead of reporting directly to the Board of Directors; (iv) relocation of his principal office to location that is more than 50 miles away from the current location of the Company s principal office; or (v) any other material breach by the Company of the employment agreement.

Death; Disability; Termination of Employment in Connection With Expiration of Employment Period. If Mr. Bentsur s employment is terminated by reason of his death or disability, or if we terminate his employment upon the normal expiration of the employment period, then he will receive his accrued obligations and any vested portion of the Initial Stock Option will remain exercisable for a period of one year following his date of termination. His outstanding Earned Milestone Awards will become fully vested and non-forfeitable. In addition, any Unearned Milestone Opportunity will continue for a period of 3 months following his termination and, to the extent that a milestone is achieved during such three-month period, the stock relating to such milestone will be issued to Mr. Bentsur or his estate, as the case may be, as fully-vested shares, rather than restricted stock, or, in our sole discretion, we may pay Mr. Bentsur an amount in cash equal to the value of such shares.

Change in Control. Upon the occurrence of a change in control, and except with respect to any awards (or Unearned Milestone Opportunities) assumed by the surviving entity or otherwise equitably converted or substituted in connection with the change in control:

the Initial Option Grant will immediately vest and become fully exercisable;
any Earned Milestone Awards will become fully vested and non-forfeitable; and
any Unearned Milestone Opportunity will expire without consideration; provided that we will grant to Mr. Bentsur, immediately prior to the effective time of the change in control, (A) 400,000 shares of fully-vested common stock in the event that he has not, as of such time, previously received any milestone awards under the Bentsur 3rd Milestone Award, and (B) 500,000 shares of vested common stock in the event that he has not, as of such time, previously received any milestone awards under Bentsur 4th Milestone Award, or, in our discretion, the cash equivalent of (A) and (B).

In the event that the Initial Option Grant, any Earned Milestone award, or any Unearned Milestone Opportunity is assumed by the surviving entity or otherwise equitably converted or substituted in connection with a change in control, then if, within one year after the effective date of the change in control, Mr. Bentsur s employment is terminated without cause or Mr. Bentsur resigns for good reason:

the Initial Option Grant will become fully vested and exercisable and will remain exercisable for a period of one year following Mr. Bentsur's date of termination;

any Earned Milestone awards will become fully vested and non-forfeitable;

24

TABLE OF CONTENTS

Unearned Milestone Awards with respect to the Bentsur 2nd and 5th Milestone Awards will continue for a period of three months after Mr. Bentsur's date of termination, and

Unearned Milestone Awards with respect to the Bentsur 3rd and 4th Milestone Awards will continue for a period of one year after Mr. Bentsur's date of termination.

To the extent that a milestone is achieved during such three-month or one-year period above, as the case may be, the stock relating to such milestone will be issued to Mr. Bentsur as fully-vested shares, rather than restricted stock. Any Unearned Milestone Opportunities which remain unearned at the end of such three-month or one-year period, as the case may be, will expire without consideration.

For purposes of Mr. Bentsur's employment agreement, as well as the 2004 Plan and 2007 Plan, Change in Control generally means: (i) the incumbent Board of Directors of the Company ceases to constitute a majority of the Board of Directors; (ii) the acquisition by any person of 30% or more ownership interest in the outstanding common stock or combined voting power of the then outstanding securities of the Company (with certain limited exceptions); or (iii) the consummation of a merger, consolidation, reorganization, recapitalization or share exchange or a sale or other disposition of all or substantially all of the assets of the Company, unless (a) the beneficial owners of the Company's stock immediately prior to the transaction continue to own 50% or more of the outstanding common stock and combined voting power of the then outstanding securities of the Company and (b) no person acquires a 30% or more ownership interest in the then outstanding common stock or combined voting power of the then outstanding securities of the Company.

Restrictive Covenants. During the one-year period after his termination of employment, Mr. Bentsur is prohibited from soliciting protected customers or employees of the Company, competing with the Company, and disclosing any of the Company's confidential information or trade secrets.

James Oliviero

We do not have an employment agreement with Mr. Oliviero. The value of accelerated stock options and restricted stock that Mr. Oliviero would receive if his employment was terminated on December 31, 2010 in association with a change in control of the Company would be \$1,014,282, which represents the fair market value of shares underlying outstanding stock options and restricted shares that would become vested upon the event, based on \$4.58 closing price as of December 31, 2010, the last trading day of the most recently completed fiscal year, less the exercise price of the stock options. For purposes of this calculation, outstanding options having an exercise price equal to or more than the closing price of our common stock on such date have a value of \$0.

TABLE OF CONTENTS

DIRECTOR COMPENSATION

Director Compensation Program

Cash Compensation. Our non-employee directors receive the following cash compensation:

From January 1, 2010 to May 31, 2010:

\$40,000 annual retainer;
\$5,000 additional annual retainer for each committee assignment;
\$25,000 additional annual retainer for service as Chairman of the Audit Committee; and
\$25,000 additional annual retainer for service as Chairman of the Board.

After May 31, 2010:

\$50,000 annual retainer;
\$20,000 additional annual retainer for service as Chairman of the Audit Committee; and
\$20,000 additional annual retainer for service as Chairman of the Board.

Each non-employee director receives reimbursement for reasonable travel expenses incurred in attending meetings of our Board of Directors and meetings of committees of our Board of Directors.

Equity Compensation. Our non-employee directors receive the following equity compensation under the Directors Equity Compensation Plan, which is a subplan of the 2007 Plan.

From January 1, 2010 to June 15, 2010:

Initial Option Grant. Non-employee directors receive options to purchase 50,000 shares of our common stock upon initial election or appointment to the Board of Directors. The initial options will vest in equal annual installments over three years, beginning on the first anniversary of the date of grant.

Re-Election Option Grant. Non-employee directors receive options to purchase 10,000 shares of our common stock upon each re-election to the Board of Directors. Such options vest as to 5,000 shares on the date of grant and as to 5,000 shares on the first anniversary of the date of grant.

Three-Year Anniversary Option Grant. Non-employee directors receive options to purchase 30,000 shares of our common stock upon completion of three years of service on the Board of Directors. Such options vest as to one-third of the shares each year beginning on the first anniversary of the date of grant. Mr. Cameron received a three-year anniversary option grant in 2010.

After June 15, 2010:

Initial Option Grant. Non-employee directors receive options to purchase 50,000 shares of our common stock upon initial election or appointment to the Board of Directors. The initial options will vest in equal annual installments over three years, beginning on the first anniversary of the date of grant. Dr. Feczko received an initial option grant in 2010 upon appointment to the Board of Directors in July 2010.

Re-Election Option Grant. Non-employee directors receive options to purchase 25,000 shares of our common stock upon each re-election to the Board of Directors. Each non-employee director, except for Dr. Feczko who was

appointed to the Board of Directors in July 2010, received a re-election option grant in 2010. Such options vest in equal annual installments over three years, beginning on the first anniversary of the date of grant.

Re-Election Stock Grant. Non-employee directors receive a restricted stock award of 15,000 shares of our common stock upon each re-election to the Board of Directors. Each non-employee director, except for Dr. Feczko who was appointed to the Board of Directors in July 2010, received a re-election restricted stock award in 2010. Such restricted stock vest in equal annual installments over three years, beginning on the first anniversary of the date of grant.

TABLE OF CONTENTS

In addition to the compensation described above, during 2010, the Board granted the following equity awards:

As additional incentive to join the Board of Directors, on July 16, 2010, the Board voted unanimously to grant Dr. Feczko 5,000 shares of restricted stock, vesting in equal annual installments over three years, beginning on the first anniversary of the date of grant; and

Following the removal of the Three-Year Anniversary Option grant from the Directors Equity Compensation Plan, in recognition of his three years of service on the Board of Directors, on September 21, 2010, the Board voted unanimously to grant Mr. Tarnok 30,000 stock options, vesting in equal annual installments over three years, beginning on the first anniversary of the date of grant.

2010 Director Compensation

The following table sets forth the cash and other compensation paid by the Company to the non-employee members of the Board of Directors for all services in all capacities during 2010.

Name	Fees Earned or Paid in Cash (\$) ⁽¹⁾	Stock Awards (\$) ⁽³⁾	Option Awards (\$) ⁽³⁾	Total (\$)
Kevin Cameron	50,000	62,700	189,723	302,423
Joseph Feczko ⁽²⁾	20,833	18,500	147,290	186,623
Wyche Fowler	50,000	62,700	83,628	196,328
Jack Kaye	70,000	62,700	83,628	216,328
Michael Tarnok	70,000	62,700	196,632	329,332

(1) Represents cash retainer for serving on our Board and committees of the Board.

In July 2010, Joseph Feczko, M.D. was appointed to the Board of Directors by unanimous vote of the directors.

(2) Represents the retainer earned in 2010 for Board of Directors services for the period from August 2010 to December 2010.

Reflects the aggregate grant date fair value of stock and option awards granted by the Company as computed under FASB ASC Topic 718. The grant date fair value of the stock awards is based on the fair market value of the

(3) underlying shares on the date of grant. The assumptions made in the valuation of the option awards are contained in Note 11 to our consolidated financial statements for 2010, which are included in our Annual Report on Form 10-K for the fiscal year 2010.

TABLE OF CONTENTS

The following table shows the number of stock and option awards granted to each director during 2010, and the grant date fair value for each award (determined in accordance with FASB ASC Topic 718):

Name	Grant Date	Stock Awards (#)	Stock Options (#)	Grant Date Fair Value of Awards (\$)
Kevin Cameron	4/25/2010		30,000	106,095
	6/16/2010		25,000	83,628
Joseph Feczko	6/16/2010	15,000		62,700
	7/16/2010		50,000	147,290
Wyche Fowler	7/16/2010	5,000		18,500
	6/16/2010		25,000	83,628
Jack Kaye	6/16/2010	15,000		62,700
	6/16/2010		25,000	83,628
Michael Tarnok	6/16/2010	15,000		62,700
	6/16/2010		25,000	83,628
	9/21/2010		30,000	113,004

As of December 31, 2010, the following aggregate number of unvested stock and option awards were held by each of our non-employee directors:

Name	Stock awards (#)	Option awards (#)
Kevin Cameron	35,000	135,000
Joseph Feczko	5,000	50,000
Wyche Fowler	35,000	135,000
Jack Kaye	35,000	135,000
Michael Tarnok	31,666	125,000

TABLE OF CONTENTS

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

The current members of our Compensation Committee are Kevin Cameron, Wyche Fowler, Jr. and Michael Tarnok. No member of our Compensation Committee during fiscal year 2010 or as of the date of this proxy statement, is or has been an officer or employee of Keryx or any of our subsidiaries, nor has any member of our Compensation Committee had any relationship with Keryx requiring further disclosure.

During the last fiscal year, none of our executive officers served as a director or member of the Compensation Committee (or other committee serving an equivalent function) of any other entity, whose executive officers either served as a member of our Compensation Committee or our Board of Directors.

TABLE OF CONTENTS

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Exchange Act requires our directors, executive officers and persons who own more than 10% of the shares of our common stock to file an initial report of ownership on Form 3 and changes in ownership on Form 4 or Form 5 with the SEC. Such officers, directors and 10% stockholders are also required by SEC rules to furnish us with copies of any Forms 3, 4 or 5 that they file. The SEC rules require us to disclose late filings of initial reports of stock ownership and changes in stock ownership by our directors, executive officers and 10% stockholders. Based solely on a review of copies of the Forms 3, 4 and 5 furnished to us by reporting persons and any written representations furnished by certain reporting persons, we believe that during the fiscal year ended December 31, 2010, all Section 16(a) filing requirements applicable to our directors, executive officers and 10% stockholders were completed in a timely manner, except for Joseph M. Feczko, M.D., where following his appointment as a director of the Company, Dr. Feczko inadvertently failed to timely file a Form 3. The required Form 3 report for Dr. Feczko was subsequently filed.

TABLE OF CONTENTS

RELATED-PERSON TRANSACTIONS

Policy

Our Board of Directors has determined that the Audit Committee is best suited to review and approve transactions with related persons, and they do so under the terms of our Related Person Transactions Policy, which is available on our website, located at www.keryx.com. According to our Related Person Transactions Policy, prior to entering into a transaction with a related person, (a) the director, executive officer, nominee or significant holder who has a material interest (or whose immediate family member has a material interest) in the transaction or (b) the business unit or function/department leader responsible for the potential transaction with a related person is required to provide notice to the Chairman of the Audit Committee of the Company (Committee Chairman) of the material facts and circumstances of the potential transaction with a related person and such information concerning the transaction as the Committee Chairman may reasonably request. If the Committee Chairman determines that the proposed transaction is a related person transaction, the proposed related person transaction must be submitted to the Audit Committee for consideration at the next Audit Committee meeting or, in those instances in which the Committee Chairman determines that it is not practicable or desirable for the Company to wait until the next Audit Committee meeting, the Committee Chairman possesses delegated authority to act between Committee meetings.

The Audit Committee will consider all of the relevant facts and circumstances available to the Audit Committee, including (if applicable) but not limited to: (a) the benefits to the Company; (b) the availability of other sources for comparable products or services; (c) the terms of the transaction; and (d) the terms available to unrelated third parties or to employees generally. No member of the Audit Committee will participate in any review, consideration or approval of any related person transaction if such member, or any of his or her immediate family members, is the related person. The Audit Committee or Chairperson, as applicable, will convey the approval or disapproval of the transaction to the Chief Executive Officer or Secretary, who will convey the decision to the appropriate persons within the Company. The Chairperson of the Audit Committee will report to the Audit Committee at the next Audit Committee meeting any approval under this policy made by the chairperson pursuant to delegated authority.

In the event we become aware of a related person transaction that has not been previously approved or previously ratified under this policy, and such transaction is pending or ongoing, it will be submitted to the Audit Committee or Chairperson, as applicable, promptly, and the Audit Committee or Chairperson will consider all of the relevant facts and circumstances available to the Audit Committee or the Chairperson as provided above. Based on the conclusions reached, the Audit Committee or Chairperson, as applicable, will evaluate all options, including but not limited to, ratification, amendment or termination of the related person transaction.

Related Person Transactions

We did not have any related person transactions in 2010, and none are currently proposed.

TABLE OF CONTENTS

STOCK OWNERSHIP OF OUR DIRECTORS, EXECUTIVE OFFICERS, AND 5% BENEFICIAL OWNERS

The following table shows information, as of April 20, 2011, concerning the beneficial ownership of our common stock by:

each person we know to be the beneficial owner of more than 5% of our common stock;
each of our current directors;
each of our NEOs shown in our Summary Compensation Table; and
all current directors and NEOs as a group.

As of April 20, 2011, there were 61,841,160 shares of our common stock outstanding. In order to calculate a stockholder's percentage of beneficial ownership, we include in the calculation those shares underlying options or warrants beneficially owned by that stockholder that are vested or that will vest within 60 days of April 20, 2011. Shares of restricted stock are deemed to be outstanding. Options or warrants held by other stockholders that are not attributed to the named beneficial owner are disregarded in this calculation. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the shares of our common stock. Unless we have indicated otherwise, each person named in the table below has sole voting power and investment power for the shares listed opposite such person's name, except to the extent authority is shared by spouses under community property laws.

Name and Address of Beneficial Owner ⁽¹⁾	Amount and Nature of Beneficial Ownership	Percentage of Shares Outstanding
Ron Bentsur ⁽²⁾	703,381	1.1 %
Kevin J. Cameron ⁽³⁾	183,333	*
Joseph M. Feczko, M.D.	25,000	*
Wyche Fowler, Jr. ⁽⁴⁾	203,333	*
Jack Kaye ⁽⁵⁾	239,733	*
James F. Oliviero ⁽⁶⁾	413,780	*
Michael P. Tarnok ⁽⁷⁾	309,433	*
All current directors and named executive officers as a group (7 persons) ⁽⁸⁾	2,077,993	3.3 %
5% Stockholders: FMR LLC	4,107,100	6.6 %

* Less than 1% of outstanding common stock.

(1) The address of each of the directors and officers listed is c/o Keryx Biopharmaceuticals, Inc., 750 Lexington Avenue, New York, New York 10022. The address of FMR LLC is 82 Devonshire Street, Boston, MA 02109.

(2) Includes 351,600 shares of our common stock issuable upon the exercise of options.

(3) Includes 98,333 shares of our common stock issuable upon the exercise of options.

(4) Includes 98,333 shares of our common stock issuable upon the exercise of options.

(5) Includes 98,333 shares of our common stock issuable upon the exercise of options.

- (6) Includes 194,625 shares of our common stock issuable upon the exercise of options.
- (7) Includes 78,333 shares of our common stock issuable upon the exercise of options.
- (8) Includes 919,557 shares of our common stock issuable upon the exercise of options.

TABLE OF CONTENTS

PROPOSAL ONE

ELECTION OF DIRECTORS; NOMINEES

Our Amended and Restated Bylaws provide that the Board of Directors shall consist of one or more members, as determined from time to time by resolution of the Board of Directors. Our Board of Directors currently consists of six members. All of our current directors have been nominated for re-election at the 2011 Annual Meeting of Stockholders by all of our independent directors. The nominated directors are: Ron Bentsur, Kevin J. Cameron, Joseph M. Feczko, M.D., Wyche Fowler, Jr., Jack Kaye, and Michael P. Tarnok. For information about each of the nominees and our Board of Directors generally, please see Corporate Governance Our Board of Directors beginning on page 4. If elected, the nominees will hold office until the next annual meeting and until a respective successor is elected and has been qualified, or until such director resigns or is removed from office. Management expects that each of the nominees will be available for re-election, but if any of them is unable to serve at the time the election occurs, your proxy will be voted for the election of another nominee to be designated by a majority of the independent directors serving on our Board of Directors.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE FOR THE ELECTION OF ALL OF THE NOMINEES FOR DIRECTORS. IF A CHOICE IS SPECIFIED ON THE PROXY BY THE STOCKHOLDER, THE SHARES WILL BE VOTED AS SPECIFIED. IF NO SPECIFICATION IS MADE, THE SHARES WILL BE VOTED FOR ALL OF THE NOMINEES. THE AFFIRMATIVE VOTE OF THE HOLDERS OF A PLURALITY OF THE SHARES OF COMMON STOCK REPRESENTED AND ENTITLED TO VOTE AT THE ANNUAL MEETING AT WHICH A QUORUM IS PRESENT IS REQUIRED FOR THE ELECTION OF THE NOMINEES.

TABLE OF CONTENTS

PROPOSAL TWO

**RATIFICATION OF APPOINTMENT OF UHY LLP AS
OUR
INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM**

The Board of Directors is submitting the selection of UHY LLP as our independent registered public accounting firm to the stockholders for ratification at our Annual Meeting. Stockholder ratification of our independent registered public accounting firm is not required by our Amended and Restated Bylaws or otherwise. If UHY LLP is not ratified as our independent registered public accounting firm by a majority of the shares present or represented by proxy, the Audit Committee will review its future selection of independent registered public accounting firm. UHY LLP will still serve as our independent registered public accounting firm for the year ending December 31, 2011, if it is not ratified by our stockholders.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE FOR RATIFICATION OF THE APPOINTMENT OF UHY LLP AS KERYX S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2011. PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE SO VOTED UNLESS THE STOCKHOLDER SPECIFIES OTHERWISE. THE AFFIRMATIVE VOTE OF THE HOLDERS OF A MAJORITY OF THE SHARES OF COMMON STOCK REPRESENTED AND ENTITLED TO VOTE AT THE ANNUAL MEETING AT WHICH A QUORUM IS PRESENT IS REQUIRED FOR RATIFICATION OF THE APPOINTMENT OF UHY LLP.

TABLE OF CONTENTS

PROPOSAL THREE

ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

The recently enacted Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the Dodd-Frank Act) provides that our stockholders may approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in accordance with the executive compensation disclosure rules contained in Item 402 of the SEC's Regulation S-K. Accordingly, we are seeking input from our stockholders with this advisory vote on the compensation of our named executive officers. The vote on this proposal is not intended to address any specific element of compensation; rather, the vote relates to the compensation of our named executive officers as disclosed in the Compensation Discussion and Analysis section and the accompanying executive compensation tables and narrative discussion contained in this proxy statement. We are providing this vote as required pursuant to Section 14A of the Securities Exchange Act of 1934.

As an advisory vote, this proposal is not binding on Keryx, the Board of Directors, or the Compensation Committee. However, the Board of Directors and Compensation Committee intend to carefully review the results of all stockholder votes and take them into consideration when making future decisions regarding executive compensation.

We believe our executive compensation program as a whole is well suited to promote our objectives in both the short and long term. As described above in the Compensation Discussion and Analysis section of this proxy statement, the Compensation Committee has designed our executive compensation program to reflect its philosophy that executive compensation should be directly linked to corporate performance with the ultimate objective of increasing long-term stockholder value. The driving philosophy and objectives behind our executive compensation programs are:

- to attract, retain, motivate and reward outstanding employees;
- to align employees' interests with those of our stockholders by creating a strong focus on stock ownership and basing pay on performance measures that drive long-term stockholder value;
- to incentivize our employees to achieve our business goals; and
- to reflect our pay for performance culture.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE COMPENSATION DISCUSSION AND ANALYSIS SECTION AND THE ACCOMPANYING COMPENSATION TABLES AND NARRATIVE DISCUSSION CONTAINED IN THIS PROXY STATEMENT.

TABLE OF CONTENTS

PROPOSAL FOUR

ADVISORY VOTE ON THE FREQUENCY OF THE ADVISORY VOTE ON COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

The Dodd-Frank Act also enables Keryx stockholders to vote, on an advisory or non-binding basis, on the frequency of the advisory vote on the compensation of our named executive officers as disclosed in accordance with the executive compensation disclosure rules contained in Item 402 of the SEC's Regulation S-K. Stockholders may choose to approve holding an advisory vote on the compensation of our named executive officers annually, biennially, or triennially. Accordingly, we are asking stockholders whether the advisory vote should occur every year, once every two years or once every three years. Stockholders may also abstain from voting. We are providing this vote as required pursuant to Section 14A of the Securities Exchange Act of 1934.

As an advisory vote, this proposal is not binding on Keryx or the Board of Directors. However, the Board of Directors intends to carefully review the results of all stockholder votes and take them into consideration when making future decisions regarding the frequency of advisory votes on compensation of our named executive officers.

Notwithstanding the Board of Directors' recommendation and the outcome of the stockholder vote, the Board of Directors may in the future decide to conduct advisory votes on a more or less frequent basis and may vary its practice based on factors such as discussions with stockholders, industry trends and the adoption of material changes to compensation programs.

While our executive compensation programs are designed to promote a long-term connection between pay and performance, after careful consideration of the frequency alternatives, the Board of Directors believes that conducting advisory votes on executive compensation on a bi-annual basis is appropriate for Keryx and its stockholders at this time.

As a biotechnology company, the Company has important milestones relating to drug development and approval that do not occur every calendar year. While executive compensation is evaluated annually, the Board of Directors also considers progress over a multi-year timeframe, which is common in small- and mid-capitalization companies in our industry. The Board of Directors believes that a vote every two years provides stockholders the opportunity to evaluate the Company's compensation program on a more thorough, longer-term basis than an annual vote, without requiring a three year wait, which would be less responsive.

The Company understands that its stockholders may have different views as to what is the best approach for the Company, and we look forward to hearing from our stockholders on this proposal.

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR A FREQUENCY OF TWO YEARS FOR
FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED
EXECUTIVE OFFICERS.**

TABLE OF CONTENTS

ADDITIONAL INFORMATION

Householding of Annual Meeting Materials

Some banks, brokers and other nominee record holders may be participating in the practice of householding proxy statements and annual reports. This means that only one copy of our proxy statement and 2011 Annual Report may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of either document to you if you contact us at: Keryx Biopharmaceuticals, Inc., 750 Lexington Avenue, New York, New York 10022, Attn: James Oliviero. You may also contact us at (212) 531-5965.

If you want to receive separate copies of the proxy statement and Annual Report in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker, or other nominee record holder, or you may contact us at the above address or phone number.

Stockholder Proposals for Our 2012 Annual Meeting

Only proper proposals under Rule 14a-8 of the Exchange Act which are timely received will be included in the proxy materials for our next annual meeting. In order to be considered timely, such proposal must be received by our Corporate Secretary, James F. Oliviero, at 750 Lexington Avenue, New York, New York 10022, no later than December 31, 2011. Stockholders may also nominate candidates to the Board of Directors pursuant to Rule 14a-11 of the Exchange Act, and such nominations will be included in the proxy materials for our next annual meeting if timely received. In order to be considered timely, such nominations must be received by Mr. Oliviero on or after January 25, 2012, and on or before February 24, 2012. We suggest that stockholders submit any stockholder proposal by certified mail, return receipt requested.

Our Amended and Restated Bylaws require stockholders to provide advance notice to the Company of any stockholder director nomination(s) and any other matter a stockholder wishes to present for action at an annual meeting of stockholders (other than matters to be included in our proxy statement, which are discussed in the previous paragraph). In order to properly bring business before an annual meeting, our Amended and Restated Bylaws require, among other things, that the stockholder submit written notice thereof complying with our Amended and Restated Bylaws to James F. Oliviero, our Corporate Secretary, at the above address, not less than 60 days nor more than 90 days prior to the anniversary of the preceding year's annual meeting. Therefore, Keryx must receive notice of a stockholder proposal submitted other than pursuant to Rule 14a-8 (as discussed above) no sooner than March 23, 2012, and no later than April 23, 2012. If a stockholder fails to provide timely notice of a proposal to be presented at our 2011 Annual Meeting of Stockholders, the proxy designated by our Board of Directors will have discretionary authority to vote on any such proposal that may come before the meeting.

Other Matters

Our Board of Directors does not know of any other matters that may come before the meeting. However, if any other matters are properly presented to the meeting, it is the intention of the person named in the accompanying proxy card to vote, or otherwise act, in accordance with their judgment on such matters.

Solicitation of Proxies

We will bear the cost of solicitation of proxies. In addition to the solicitation of proxies by mail, our officers and employees may solicit proxies in person or by telephone. We may reimburse brokers or persons holding stock in their names, or in the names of their nominees, for their expenses in sending proxies and proxy material to beneficial owners.

Incorporation of Information by Reference

The Compensation Committee Report and the Audit Committee Report contained in this proxy statement are not deemed filed with the SEC and shall not be deemed incorporated by reference into any prior or future filings made by us under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate such information by reference.

37

TABLE OF CONTENTS

TABLE OF CONTENTS
